MedTrace Logo

A Study of RD14-01 in Patients With Advanced Solid Tumors

NCT05748938 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2023-03-01

No results posted yet for this study

Summary

This study will evaluate the safety and tolerability of RD14-01, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ advanced solid tumors.

Conditions

Interventions

BIOLOGICAL

RD14-01

ROR1 Targeted CAR-T cells

Sponsors & Collaborators

  • 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

    lead OTHER

Principal Investigators

  • Sanbin Wang, Doctor · 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-08
Primary Completion
2024-08-08
Completion
2025-02-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05748938 on ClinicalTrials.gov